Randomized, Open Label, Phase 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

Trial Profile

Randomized, Open Label, Phase 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Pegargiminase (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms TACE
  • Sponsors Polaris Pharmaceuticals
  • Most Recent Events

    • 17 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 07 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
    • 07 Feb 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top